Drug intelligence / Profile preview

parathiazine

Development stage: Unknown
Modality: Small Molecules

Overview

Parathiazine is a synthetic small molecule belonging to the phenothiazine class. Its chemical structure is 10-(2-(1-pyrrolidyl)ethyl)phenothiazine (C18H20N2S)[6][10]. Parathiazine has been investigated as a pharmaceutical agent but is not widely marketed or approved for clinical use in major regions. It shares structural similarity with other phenothiazines, which are known for their antihistaminic and antipsychotic properties; however, specific indications and detailed pharmacological actions of parathiazine itself are not well documented in current medical literature[6][10].

Other names: parathiazinepyrathiazineparatiazinapyrathiazinum10-(2-(1-pyrrolidyl)ethyl)phenothiazine

Targets

M1 (Muscarinic acetylcholine receptor M1)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on parathiazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on parathiazine.

Explore the full profile